RCC is a common malignancy with an incidence that has risen over the last 30 years largely due to incidental findings on imaging. During this time, the evaluation and management of RCC has evolved due to a greater understanding of the genetics of the disease, changes in the TNM staging system, and a trend to less invasive and organ-sparing surgical treatments. Minimally invasive procedures will continue to be at the forefront of treatment in the decades to come. With the advent of biologic response modifiers, additional therapies are now available for patients with metastatic RCC. Nurses and physicians caring for patients with RCC must be knowledgeable about these newer treatment modalities, which patients are appropriate candidates for such therapies, anticipated response rates, and the management of potential adverse effects. A multidisciplinary approach, which includes nurses and allied personnel, will continue to be vital in the management of these patients.